Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir

Journal of Clinical Investigation

Volumn 124, Issue 1, 2014, Pages 262-272

  Coriat, Romain ^a,b   Alexandre, Jérôme ^a,b   Nicco, Carole ^a   Quinquis, Laurent ^c   Benoit, Evelyne ^d   Chéreau, Christiane ^a   Lemaréchal, Hervé ^e   Mir, Olivier ^a,b   Borderie, Didier ^e   Tréluyer, Jean Marc ^a   Weill, Bernard ^a   Coste, Joel ^c   Goldwasser, François ^a,b   Batteux, Frédéric ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CERIA (Centre for Research on Angiogenesis Inhibitors)   (France)

^c HÔTEL DIEU   (France)

^d CNRS   (France)

^e NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; MANGAFODIPIR; OXALIPLATIN;

AGED; ANIMAL EXPERIMENT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPESTHESIA; MALE; MEMBRANE STEADY POTENTIAL; MOTOR DYSFUNCTION; MOUSE; MULTIPLE CYCLE TREATMENT; MUSCLE ACTION POTENTIAL; MYELINATED NERVE; MYELINATION; NERVE FIBER; NEUROMUSCULAR FUNCTION; NOCICEPTION; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); POTASSIUM CHANNELOPATHY; PRIORITY JOURNAL; ROTAROD TEST; SENSORY DYSFUNCTION;

EID: 84892945267     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68730     Document Type: Article

References (49)

1. Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun. 1994;203(2):1175-1180
2. Laurent A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65(3):948-956
3. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002; 29(5 suppl 15):21-33
4. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889-901
5. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin- induced peripheral nerve damage. Cancer Treat Rev. 2008;34(4):368-377
6. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998;25(2 suppl 5):13-22
7. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85(5):2293-2297
8. Holmes J, et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci. 1998;46(2):342-351
9. Carozzi VA, Marmiroli P, Cavaletti G. The role of oxidative stress and anti-oxidant treatment in platinum- induced peripheral neurotoxicity. Curr Cancer Drug Targets. 2010;10(7):670-682
10. Gamelin L, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10(12 pt 1):4055-4061
11. Lersch C, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2002;2(1):54-58
12. Mollman JE. Cisplatin neurotoxicity. N Engl J Med. 1990;322(2):126-127
13. Goss-Sampson MA, MacEvilly CJ, Muller DP. Longitudinal studies of the neurobiology of vitamin E and other antioxidant systems, and neurological function in the vitamin E deficient rat. J Neurol Sci. 1988;87(1):25-35
14. Cascinu S, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double- blind, placebo-controlled trial. J Clin Oncol. 2002; 20(16):3478-3483
15. Yang TT, Wang SJ. Pyridoxine inhibits depolarization- evoked glutamate release in nerve terminals from rat cerebral cortex: a possible neuroprotective mechanism? J Pharmacol Exp Ther. 2009;331(1):244-254
16. Bedda S, et al. Mangafodipir prevents liver injury induced by acetaminophen in the mouse. J Hepatol. 2003;39(5):765-772
17. Coriat R, et al. Mangafodipir protects against hepatic ischemia-reperfusion injury in mice. PLoS One. 2011;6(11):e27005
18. Alexandre J, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst. 2006;98(4):236-244
19. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34(7):934-938
20. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002; 20(7):1767-1774
21. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406(1):25-32
22. Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities of sensory nerve function associated with oxaliplatin- induced neurotoxicity. J Clin Oncol. 2009; 27(8):1243-1249
23. Kiernan MC. The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer. 2007;43(18):2631-2633
24. Descoeur J, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011;3(5):266-278
25. Dimitrov AG, Dimitrova NA. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. Muscle Nerve. 2012;45(3):403-411
26. Thibault K, et al. Cortical effect of oxaliplatin associated with sustained neuropathic pain: exacerbation of cortical activity and down-regulation of potassium channel expression in somatosensory cortex. Pain. 2012;153(8):1636-1647
27. Kagiava A, Kosmidis EK, Theophilidis G. Oxaliplatin- induced hyperexcitation of rat sciatic nerve fibers: an intra-Axonal study. Anticancer Agents Med Chem. 2013;13(2):373-379
28. Ang CD, et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst. 2008;(3):CD004573
29. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011; 77(10):980-986
30. Andre T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351
31. Broomand A, Jerremalm E, Yachnin J, Ehrsson H, Elinder F. Oxaliplatin neurotoxicity - no general ion channel surface-charge effect. J Negat Results Biomed. 2009;8:2
32. Karlsson JO, et al. Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium. Acta Radiol. 2001;42(6):540-547
33. Hirt D, et al. Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. Ther Drug Monit. 2009;31(5):557-565
34. Karlsson JO, Adolfsson K, Thelin B, Jynge P, Andersson RG, Falkmer UG. First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-A translational study. Transl Oncol. 2012;5(1):32-38
35. Perl DP, Olanow CW. The neuropathology of manganese- induced Parkinsonism. J Neuropathol Exp Neurol. 2007;66(8):675-682
36. Rovetta F, et al. Organ-specific manganese toxicity: a comparative in vitro study on five cellular models exposed to MnCl(2). Toxicol In Vitro. 2007; 21(2):284-292
37. Miraucourt LS, Moisset X, Dallel R, Voisin DL. Glycine inhibitory dysfunction induces a selectively dynamic, morphine-resistant, and neurokinin 1 receptor-independent mechanical allodynia. J Neurosci. 2009;29(8):2519-2527
38. Ta LE, Low PA, Windebank AJ. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain. 2009;5:9
39. Boerio D, Greensmith L, Bostock H. Excitability properties of motor axons in the maturing mouse. J Peripher Nerv Syst. 2009;14(1):45-53
40. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000;23(3):399-409
41. Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst. 2008;13(1):7-26
42. Lefaucheur JP, Boerio D, Hogrel JY, Creange A. [Nerve excitability studies in the assessment of dysimmune neuropathies]. Rev Neurol (Paris). 2006; 162(spec no 1):3S17-3S26
43. Betz WJ, Mao F, Bewick GS. Activity-dependent fluorescent staining and destaining of living vertebrate motor nerve terminals. J Neurosci. 1992;12(2):363-375
44. Witko-Sarsat V, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49(5):1304-1313
45. Gehan EA. Design of controlled clinical trials: use of historical controls. Cancer Treat Rep. 1982; 66(5):1089-1093
46. de Gramont A, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-2947
47. Maindrault-Goebel F, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 1999;35(9):1338-1342
48. Grothey A, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2010;29(4):421-427
49. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994; 233:380-385.